Project Grant R01HL174940
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$785K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This $784,206 federal Project Grant award issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of the CSF-1/CSF-1R axis in myocardial infarction (MI) repair and remodeling. The research aims to examine the in vivo effects of macrophage-specific CSF-1R activation, investigate the role of fibroblast-derived CSF-1, evaluate the therapeutic potential of early CSF-1/CSF-1R axis activation, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism following a myocardial infarction. The 4-year research project aims to shed novel insight into how bone marrow macrophages that infiltrate the infarcted heart disrupt cardiac muscle energetics and function, and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research into the Hippo-YAP signaling pathway and its role in cardiac regenerative repair. The $693,261 award, effective January 10, 2025 through December 31, 2028, aims to develop gene therapy strategies that can enhance cardiac function and promote regenerative responses following myocardial infarction. The research will...
The $740,037 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to investigate the role of cardiac fibroblasts in regulating angiogenesis following myocardial infarction. The key objectives are to: 1) Evaluate the function of anti-angiogenic factors like collagen type XVIII (COL18A1) in cardiac fibroblasts after a heart attack, and 2) Determine if expression of pro-angiogenic factors...
This federal Project Grant award, identified as R01HL171118, is funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $847,164 grant supports research to investigate the underlying mechanisms of pathologic remodeling of the ventricular conduction system, particularly in the context of common acquired cardiomyopathies such as those seen in patients with hypertension, diabetes, and obesity. The research, conducted by...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $777,258 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research focused on improving the understanding of heart failure in patients with hypertrophic cardiomyopathy. The project aims to leverage advanced cardiac magnetic resonance imaging (CMR) techniques, including exercise CMR, to characterize the underlying...
This $170,555 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the immunomodulatory effects of anti-fibroblast activation protein (FAP) chimeric antigen receptor (CAR) T cells in the treatment of cardiac fibrosis. The project, awarded to The Washington University, seeks to delineate the feasibility of T cell-engaging therapies, such as FAP CAR T cells and bispecific T cell...
This R03 Project Grant for $125,250 was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant funds a 2-year research project led by Dr. James Rhee at Massachusetts General Hospital (MGH) to study the role of the cytokine FAM3D in regulating cardiac fibrosis and inflammation in heart failure. The research aims to characterize how FAM3D affects cardiac fibroblasts and the lymphatic system, and evaluate its...
This Project Grant award of $678,445.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to investigate the role of the novel protein C5ORF51 (C5X) in regulating cardiomyocyte function and homeostasis. The overarching hypothesis is that C5X, as a modulator of core cardiac transcription factors, plays a critical role in cardiomyogenesis and maintaining normal cardiac function. The research project aims to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) in the amount of $1,510,312.00 supports research at the Albert Einstein College of Medicine to elucidate the role of the dense fibrillar component (DFC) of the nucleolus in ribosomal RNA (rRNA) modification and processing. The research aims to determine how the DFC forms, identify the mechanism of cotranscriptional rRNA modification, and define the impact of the...